Center for Scientific Review; Notice of Closed Meetings, 43605 [2012-18055]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 143 / Wednesday, July 25, 2012 / Notices
If you are interested in attending,
please register at the following link:
https://respond.niaid.nih.gov/
conferences/AMDW/Pages/default.aspx
by September 10, 2012. There is no
registration fee for the workshop. Early
registration is recommended because
seating is limited. If you need special
accommodations due to a disability,
please contact Dr. Judy Hewitt (see FOR
FURTHER INFORMATION CONTACT) at least 7
days in advance of the workshop.
FOR FURTHER INFORMATION CONTACT: Dr.
Judy Hewitt, Office of Biodefense
Research Affairs, Division of
Microbiology and Infectious Diseases,
NIAID, at telephone 301–402–4197 or
telefax 301–480–1263 or email
AMworkshopSep2012@mail.nih.gov
(Subject line: Animal Model Workshop).
Conflict: Healthcare Delivery and
Methodologies.
Date: August 28, 2012.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Melinda Jenkins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3156,
MSC 7770, Bethesda, MD 20892, 301–437–
7872, jenkinsml2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 18, 2012.
Lawrence A. Tabak,
Deputy Director, NIH.
Dated: July 18, 2012.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–18168 Filed 7–24–12; 8:45 am]
[FR Doc. 2012–18055 Filed 7–24–12; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Prospective Grant of Exclusive
License: Use of Glucocerebrosidase
Activators for the Treatment of
Gaucher Disease and Central Nervous
System Proteinopathies, Including
Parkinson’s Disease
srobinson on DSK4SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Biology.
Date: August 14, 2012.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Charles Morrow, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6202, MSC 7804, Bethesda, MD
20892, 301–451–4467,
morrowcs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
VerDate Mar<15>2010
17:49 Jul 24, 2012
Jkt 226001
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
evaluation option license to Lysosomal
Therapeutics, Inc., a company having a
place of business in Boston,
Massachusetts, to practice the
inventions embodied in U.S. Provisional
Patent Application No. 61/420,946, filed
December 8, 2010 (HHS Ref. No. E–257–
2010/0–US–01) and PCT Patent
Application No. PCT/US2011/063928,
filed December 8, 2011 (HHS Ref. No.
E–257–2010/0–PCT–02), both entitled
‘‘Substituted Pyrazolopyrimidines as
Glucocerebrosidase Activators.’’ The
patent rights in these inventions have
been assigned to the United States of
America. The prospective exclusive
evaluation option license territory may
be ‘‘worldwide’’, and the field of use
may be limited to ‘‘Treatment of
Gaucher disease and human central
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
43605
nervous system proteinopathies,
including without limitation
Parkinson’s disease.’’ Upon the
expiration or termination of the
exclusive evaluation option license,
Lysosomal Therapeutics, Inc. will have
the right to execute an exclusive patent
commercialization license which will
supersede and replace the exclusive
evaluation option license with no
greater field of use and territory than
granted in the evaluation license.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
August 9, 2012 will be considered.
ADDRESSES: Requests for copies of the
patent application(s), inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Tara L. Kirby, Ph.D., Senior Licensing
and Patenting Manager, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4426; Facsimile:
(301) 402–0220; Email:
tarak@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: Gaucher
disease is a rare lysosomal storage
disease caused by mutations in the
glucocerebrosidase (GCase) gene; GCase
is localized in the lysosome and is
responsible for the breakdown of
glucocerebroside, an intermediate in
glycolipid metabolism. This technology
provides small molecule activators of
GCase that facilitate the proper folding
of GCase and its transport to the
lysosome, without inhibiting its activity
in the lysosome. Thus, these
compounds are extremely promising
candidates for the development of a
small molecule drug to treat Gaucher
disease. Mutations in the GCase gene
have also been associated with the
development of Parkinson’s disease, and
therefore, these compounds may also be
useful for the treatment of Parkinson’s
disease. It is also possible that these
compounds could be utilized to treat
other proteinopathy-based diseases.
The prospective exclusive evaluation
option license will comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR 404.7. The prospective
exclusive evaluation option license may
be granted unless within fifteen (15)
days from the date of this published
notice, the NIH receives written
E:\FR\FM\25JYN1.SGM
25JYN1
]]>Agencies
[Federal Register Volume 77, Number 143 (Wednesday, July 25, 2012)]
[Notices]
[Page 43605]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-18055]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cancer Biology.
Date: August 14, 2012.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Charles Morrow, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, 301-451-
4467, morrowcs@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Healthcare Delivery and Methodologies.
Date: August 28, 2012.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Melinda Jenkins, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3156, MSC 7770, Bethesda, MD
20892, 301-437-7872, jenkinsml2@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: July 18, 2012.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-18055 Filed 7-24-12; 8:45 am]
BILLING CODE 4140-01-P
